Showing results (81-90 of 167) with videos related to
Sort By:
Pageof 17
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.Cell|December 2, 2017
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung CancerMichael J Topper, Michelle Vaz, Katherine B Chiappinelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 TherapyMatthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C Osorio, Kathryn C Arbour, Dung T Le, et al.Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.Pageof 17